- GLOW contains GHK-Cu, BPC-157 and TB-500. KLOW adds KPV. Only one of those four compounds, GHK-Cu, has any human evidence at all; the other three are graded D here, meaning preclinical animal data only.
- GHK-Cu's human evidence base is topical cosmetic dermatology applied to the skin. The blends are injected, a route for which GHK-Cu has no human trial evidence, so the strongest ingredient's evidence does not carry over.
- A blend cannot inherit the evidence of its strongest ingredient. Combining a compound with early human topical data and three compounds with none produces a product with no evidence as a product, not an average of the four.
- No component has meaningful female-specific evidence. The number of studies reporting sex-stratified outcomes is 0 for GHK-Cu, 0 for BPC-157, 2 for TB-500 and 0 for KPV, and no study has looked at either blend as a blend in women.
GLOW and KLOW are among the most searched blends in the research-peptide market, usually described in terms of skin, healing and visible aging. They are also a useful teaching case, because the gap between how a blend is marketed and what its components have actually been shown to do is unusually wide and unusually easy to demonstrate.
This is an evidence article, not a recommendation. These are research-use compounds, not for human or veterinary use, and nothing here is dosing guidance or medical advice.
What is in them
The names are vendor labels rather than scientific ones, and they describe the mix directly once you know the abbreviations.
- GLOW is GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg.
- KLOW is the same three plus KPV 10mg. The K is the addition.
- Wolverine, frequently mentioned alongside them, drops the copper peptide and is BPC-157 plus TB-500 only.
The evidence, component by component
The honest way to assess a blend is to refuse to assess it as one thing. Here is each ingredient with its own grade and the study counts shown on its profile: total indexed studies, how many our automated index tags as female-specific, and, the number that actually matters, how many reported outcomes broken down by sex.
| Component | Grade | Indexed studies | Female-tagged | Sex-stratified | Human evidence? |
|---|---|---|---|---|---|
| GHK-Cu | C | 81 | 0 | 0 | Yes, early human, and topical |
| BPC-157 | D | 211 | 21 | 0 | No, preclinical animal only |
| TB-500 | D | 925 | 172 | 2 | No, preclinical animal only |
| KPV | D | 47 | 2 | 0 | No, preclinical animal only |
The route problem
This is the part that gets left out, and it matters more than the grade table. GHK-Cu is the component doing the persuasive work, and its human evidence is real: cosmetic dermatology studies, skewing heavily female because that is who enrolls in skin-aging research, reporting effects on skin appearance. That is why its female-evidence field reads evidence rather than unstudied, and why its menopause field does too.
Every one of those studies applied it to the skin. The route recorded for GHK-Cu in this database is topical, singular, because that is the only route with human data behind it. The blends are injected. Taking evidence generated by a cream and transferring it to a subcutaneous injection changes absorption, distribution, systemic exposure and the entire safety question, and there is no human trial bridging the two.
"GHK-Cu has clinical evidence" and "an injected GHK-Cu blend has clinical evidence" are different statements, and only the first is true. Route is not a delivery detail, it is part of what was tested. This is covered in more depth in the guide on how route changes the evidence.
Why blends are harder to judge, not easier
A blend is often presented as a shortcut, several actives for one purchase. From an evidence standpoint it is the opposite, and for reasons that hold regardless of what the components are.
- Attribution is impossible. If something improves, you cannot tell which of three or four compounds did it, or whether the combination did something none of them does alone.
- Adverse events are equally unattributable. If something goes wrong, the same problem runs in reverse, and you have no way to isolate and stop the responsible ingredient.
- Interactions are unstudied. Combining compounds can change how each behaves. For these blends, no study has examined the combination as a combination, so the interaction question is open by default.
- Evidence does not average. A grade C ingredient and three grade D ingredients do not produce a grade C product. The blend has no grade of its own, which is why this database lists blends as products that link to their constituents rather than as reviewed compounds with a female-evidence block.
What this means for women specifically
The female-tagged column looks busier than it is. TB-500 carries 172 female-tagged studies and BPC-157 carries 21, which sounds like a body of evidence until you notice the next column: the sex-stratified counts are 2 and 0. Almost none of that literature reported its results by sex, so it tells you women were somewhere in the sample, not what happened to them. GHK-Cu reads 0 female-tagged, but that zero is a known indexing artifact, the older dermatology literature is poorly tagged for sex, and the same point is made on the copper peptides profile. Its real relevance to women is qualitative: cosmetic skin research enrolls women, which is a hand-authored judgment rather than a counted result.
For BPC-157 in particular, the female-evidence type is recorded as none, and the reasoning is set out in BPC-157 in women. No study has examined any of these compounds across the menstrual cycle, in pregnancy, or by menopausal stage. If you are evaluating one of these blends for skin or visible aging at midlife, the relevant evidence for three of the four ingredients does not exist.
Where we stand on this
This site earns affiliate revenue, and these blends are among the products we link to. Writing a sceptical evidence ledger for something we may be paid to refer is the only version of this article worth publishing: a grading rubric that a revenue-generating product is exempt from is not a rubric.
None of the above says these compounds do nothing. It says the evidence to know is largely absent, and that the confident copy written about these blends is not drawn from studies. The compounds are legitimately interesting, GHK-Cu especially, and the topical dermatology literature is worth reading on its own terms. What that literature cannot do is underwrite an injected four-component mix that nobody has tested.